# Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pyrotinib-plus-capecitabine-versus-lapatinib-plus-capecitabine-for-the-treatment/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Binghe Xu,Min Yan,Fei Ma,Xichun Hu,Jifeng Feng,Quchang Ouyang,Zhongsheng Tong,Huiping Li,Qingyuan Zhang,Tao Sun,Xian Wang,Yongmei Yin,Ying Cheng,Wěi Li,Yuanting Gu,Qianjun Chen,Jinping Liu,Jing Cheng,Cuizhi Geng,Shukui Qin,Shusen Wang,Jinsong Lu,Kunwei Shen,Qiang Liu,Xiaojia Wang,Hong Wang,Ting Luo,Jin Yang,Yudong Wu,Zhiyong Yu,Xiaoyu Zhu,Chunxia Chen,Jianjun Zou |
| Citations | 401 |
| DOI | 10.1016/s1470-2045(20)30702-6 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3127064904 |
| PMID | 33581774 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Ying Cheng](https://scholariq.org/researchers/ying-cheng/)
- [Hong Wang](https://scholariq.org/researchers/hong-wang-2/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Paper topics

- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.